Elevating Biomarker Statistics to Influence Decision-Making
A Talk by Tine Descamps (Lead CDx and Biomarker Statistician, Bayer)
About this Talk
Precision medicine and targeted therapies are an increasingly growing field in the pharmaceutical industry, with a big potential for using biomarkers to increase efficiency and optimize the output of clinical trials. The potential of a biomarker strategy on the compound level is not fully exploited yet, precision medicine objectives are typically defined as tertiary or explorative only. To achieve this goal the biomarker statistician is a key partner. The current limited visibility and less familiar nature of this data creates additional challenges for the biomarker statistician to make full use of their strategic role. Here we want to outline a strategy on how to elevate biomarker statistics to guide and support decision-making using exploratory data. At the center of the strategy will always be the data.
The key to influencing decisions starts with demystifying biomarkers. Effective communication is essential not only to explain the generated results but also their meaning and potential effect on more familiar clinical trial outputs. The less exotic the data becomes, the easier it is for others to understand their importance and value. Transferring knowledge through workshops and training is key, it will not only carry over the passion for biomarkers but also create visibility for the biomarker statistician. Visibility and the resulting network combined create the potential of a voice for the biomarker statistician as a valued strategic partner for decision-making.
